Topics:

FDA Approves New Imaging System to Enhance Cervical Cancer Detection

FDA Approves New Imaging System to Enhance Cervical Cancer Detection

BD Diagnostics recently announced that it received US Food and Drug Administration (FDA) Premarket Approval for the BD FocalPoint GS Imaging System. This innovative new system is designed to enhance cervical cancer screening for cytology laboratories using the BD SurePath Pap test slides to detect evidence of squamous carcinoma, adenocarcinoma and their usual precursor conditions.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.